| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027 |
| 06 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
THIRD AMENDED AND RESTATED BY-LAWS of VTV THERAPEUTICS INC. (A Delaware Corporation) TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 STOCKHOLDERS 3 ARTICLE 3 DIRECTORS 9 ARTICLE 4 COMMITTEES OF THE BOARD 15 ARTICLE 5 OFFICERS 15... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 |
| 29 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 26, 2026, vTv Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below: |
| 13 May 2026 |
8-K: Other Events
We have acted as special counsel to vTv Therapeutics Inc., a Delaware corporation (the “Company”), in connection with the sale from time to time of shares of the Company’s Class A common stock, par value $0.01 per share, having an aggreg... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 |
| 10 Mar 2026 |
8-K: Regulation FD Disclosure
1Nasdaq: VTVT Committed to Improving the Lives of People with Diabetes March 2026 |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
1Nasdaq: VTVT Committed to Improving the Lives of People with Diabetes February 2026 |
| 02 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
On January 30, 2026, vTv Therapeutics LLC (“vTv LLC” or the "Company"), a subsidiary of vTv Therapeutics Inc., entered into the Second Amendment to License Agreement with Newsoara Biopharma Co., Ltd. (“Newsoara”) (the “Second Amendment”)... |
| 19 Dec 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
FIRST AMENDEMENT TO THE SECOND AMENDED AND RESTATED BY-LAWS OF VTV THERAPEUTICS INC. This First Amendment to the Second Amended and Restated By-Laws of vTv Therapeutics Inc., a Delaware corporation (the “Corporation”), is made as of this... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 |
| 10 Sep 2025 |
8-K: Regulation FD Disclosure
On September 10, 2025, vTv Therapeutics, Inc., (the "Company") will participate in a fireside chat from 2:35 PM - 3:10 PM EST during the Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will be hosted live via a... |
| 02 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
THE OFFER AND SALE OF THIS SECURITY AND THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAW OF ANY STATE OF THE UNITED STATES. THIS SECURITY A... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
HIGH POINT, N.C., August 12, 2025 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin ... |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2025, vTv Therapeutics Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below: |
| 19 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, dated as of May 12, 2025, by and between vTv Therapeutics LLC, a Delaware limited liability company (the “Company”), and Michael Tung (the “Executive”), and for certain purposes specified... |
| 16 May 2025 |
8-K: Regulation FD Disclosure
1 Nasdaq: VTVT Improving the Lives of Millions of People Living with Type 1 Diabetes May 2025 |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) |
| 11 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 11, 2025, the Board of Directors of vTv Therapeutics Inc. (the “Company”) appointed Barry K. Brown, age 64, as interim principal financial officer effective immediately. During the period Mr. Brown serves as interim principal fi... |
Loading...